Program
linzagolix
Also written as “KLH-2109”, “75 mg linzagolix tablet” and “200 mg linzagolix tablet”.
Its studies are mostly in Endometriosis · Leiomyoma · Renal Insufficiency · Hepatic Insufficiency, led by 2 companies.
Drug pageLinzagolix: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Kissei Pharmaceuticalits history only | 111 open or running | phase 3since Jun 6, 2019 | Jul 14, 2011 | Nov 2027phase 3 · NCT07015268 |
| ObsEva | 30 open or running | phase 2since May 3, 2016 | May 3, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of ObsEva only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 3, 2016First study: phase 2 study in EndometriosisFirst studyNCT02778399 · 328 enrolled · United States, Poland, Russian Federation and more
- Dec 9, 2017Named linzagolixINNProposed as its International Nonproprietary Name in WHO's List 118 · before, KLH-2109, OBE2109
- May 20, 20192 phase 1 studiesNCT03961932, NCT03962049
TargetBeta
“Gonadotropin-releasing hormone receptor antagonist; Gonadotropin-releasing hormone receptor antagonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 3 ObsEva leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03962049Hepatic Insufficiency · United States | 1 | Completed | Oct 23, 2019 | 24 |
| NCT03961932Renal Insufficiency · United States | 1 | Completed | Jan 22, 2020 | 33 |
| NCT02778399Endometriosis · United States, Poland, Russian Federation and more | 2 | Completed | Apr 2018 | 328 |
How it is read
Names in the registry
- “KLH-2109”, 11 entries
- “75 mg linzagolix tablet”, 4 entries
- “200 mg linzagolix tablet”, 4 entries
- “Linzagolix”, 2 entries
- “OBE2109”, 1 entry
Conditions, from the studies’ own filings
- Endometriosis, 10 studies
- Leiomyoma, 2 studies
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.